Condition
Type II Diabetes
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 65 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
60 shownThe GRoceries Aimed at Increasing Nutrition StudyNCT07167004 · 2025-10-14
RECRUITINGLifestyle Medicine: Establishing Clinical Approaches to Chronic Disease for Rural PatientsNCT06049420 · 2025-02-01
RECRUITINGEfficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes MellitusNCT05028140 · 2024-10-08
RECRUITINGEffect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCTNCT05708859 · 2024-01-02
RECRUITINGDundrum Forensic Redevelopment Evaluation Study: D-FOREST Study.NCT05074732 · 2019-12-01
RECRUITINGHeart-Kidney-Diabetes Multidisciplinary Care MOdels for CardiovascuLar Health In Patients With Chronic Kidney DiSease and Diabetes: A PragmaTIC Cluster Randomized Controlled Trial (HOLISTIC)NCT07811427 · 2026-12-01
NOT_YET_RECRUITINGEffectiveness of an mHealth Mobile AppNCT06387433 · 2024-03-20
UNKNOWNPassive Stretching Versus Electrical Stimulation on Glucose Level, in Elderly With Type II DiabetesNCT06245252 · 2024-02-10
UNKNOWNSafety, Pharmacokinetics, and Food Effect of PS1 in SubjectsNCT05176210 · 2023-12-22
COMPLETEDThe Effects of Raspberry Leaf Tea on Blood Glucose ControlNCT06385626 · 2023-12-18
UNKNOWNClinical Trial to Investigate the Pharmacokinetics and Safety After Oral Administration of CKD-378 and Co-administration of D745, D150, D029 in Healthy AdultsNCT05881213 · 2023-06-01
COMPLETEDA Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-378NCT05741437 · 2023-04-11
COMPLETEDBurger Allen Exercises in Knee OA With Type II DiabetesNCT05878587 · 2023-03-31
COMPLETEDAssociation Between Natural Hypoglycemic Foods and Blood Sugar Level: A Pilot StudyNCT05272839 · 2022-04-01
UNKNOWNA Study to Assess the Bioequivalence of Fixed Dose Combination of HR20033 Relative to Co-administration of the Individual Components in Healthy Chinese SubjectsNCT05108350 · 2021-11-09
UNKNOWNA Study to Assess the Effect of Food on HR20033 and Pharmacokinetic After Multiple Dose in Healthy VolunteersNCT05120219 · 2021-10-13
UNKNOWNImpact of the Rapid Normalization of Chronic Hyperglycemia and the Practice of Moderate Physical Activity on the "Receptor Activator of Nuclear Factor-kappa B Ligand / Osteoprotégérine (RANKL / OPG) System in Patients Living With Type II DiabetesNCT04893135 · 2021-10-11
COMPLETEDDietary Approaches to Stop Hypertension for DiabetesNCT04286555 · 2021-06-02
COMPLETEDA Study to Investigate the PK and Safety of CKD-393NCT04768673 · 2021-03-26
COMPLETEDMass Balance and Biotransformation of [14C]HSK7653 in HumanNCT04540016 · 2020-11-15
COMPLETEDEvaluation of Effects of Dibifree® on Regulation of Blood Sugar and HbA1c in Patients With Type II DiabetesNCT06224803 · 2020-08-26
COMPLETEDEducational Intervention Targeting Statin Therapy and Compliance in Diabetic PatientsNCT04499846 · 2020-06-11
COMPLETEDINTEGRATE-D: A Pilot Test to Support Integration of Medical and Psychosocial Care for People With Type II DiabetesNCT04461405 · 2020-03-01
COMPLETEDSOKARY Mobile Application With Type II DiabetesNCT04843592 · 2019-08-30
COMPLETEDPeer Support Dyads in ChurchesNCT03463941 · 2019-01-05
COMPLETEDSupplementation of Brown Seaweed on Insulin Resistance of NAFLD Patients With Pre- or Type 2-DiabetesNCT04715776 · 2018-12-10
UNKNOWNPharmacokinetics and Safety/Tolerability After Oral Administration of CKD-387 and D484 in Healthy AdultsNCT03646799 · 2018-08-30
UNKNOWNEffects of GLP-1 Agonists on CArdiac Steatosis Evaluated by Magnetic Resonance ImagingNCT03498001 · 2018-04-16
COMPLETEDDetermination of the Optimum Cut-off Value of Type 2 Diabetes Diagnosis Among Chinese Population(SENSIBLE STUDY II)NCT03024788 · 2017-01-01
UNKNOWNRole of Gastrointestinal Microbes on Digestion of Resistant Starch and Tryptophan Availability to HumansNCT02974699 · 2017-01-01
UNKNOWNProviding Preventive Periodontal Treatment to Hospitalized Patients With DiabetesNCT02914743 · 2016-11-01
COMPLETEDDouble Blind Placebo Study of JARDIANCE® (Empagliflozin) in Prehypertensives Type II DiabeticsNCT01001962 · 2016-01-01
UNKNOWNSalivary Transcriptome Biomarkers for Early Diabetes DetectionNCT02673762 · 2016-01-01
UNKNOWNPersonalized Health Planning in Shared Medical Appointments for Individuals With Type II Diabetes Pilot StudyNCT02471794 · 2015-12-01
COMPLETEDClinical Trial of YH14755 in Subjects With Dyslipidemia and Type II DiabetesNCT02586129 · 2015-11-04
COMPLETEDMetformin/Atorvastatin Combination Therapy in Subjects With Type II Diabetes and Dyslipidemia (Phase 3)NCT02947620 · 2015-08-01
COMPLETEDEffect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or InsulinNCT02429258 · 2015-05-01
COMPLETEDMobile Unit Screening of Pathologies Associated With Chronic Diseases - FeasibilityNCT02214056 · 2015-02-01
COMPLETEDClinical Trial for PB-119 in Healthy Subjects (Phase I)NCT02084251 · 2014-02-01
COMPLETEDJanuvia (Sitagliptin) in Healing Chronic Diabetic Foot UlcersNCT02015910 · 2014-01-01
TERMINATEDInitial Clinical Evaluation of an Endoscopic Therapy for Type 2 DiabetesNCT01927562 · 2013-07-13
COMPLETEDMeasuring the Preferences of Patients With Type II Diabetes Using Best-worst Scaling and Discrete Choice ExperimentNCT02637622 · 2013-07-01
COMPLETEDMeasuring the Priorities of Patients With Type II Diabetes Using Likert Scale and Best-worst ScalingNCT02637609 · 2013-07-01
COMPLETEDFatty Liver Study in Patients With Type II DiabetesNCT02365233 · 2013-05-01
TERMINATEDEpithelial Sodium Channel (ENaC) as a Novel Mechanism for Hypertension and Volume Expansion in Type 2 DiabetesNCT01804777 · 2013-03-01
TERMINATEDUsing EEG Operant Conditioning to Improve Trait Self-Control and Promote Healthy BehaviorNCT01801254 · 2013-02-01
COMPLETEDType II Diabetes Influence on Left Ventricular Remodeling and Outcomes in Patients Undergoing Aortic Valve Replacement Surgery.NCT01862237 · 2012-12-01
UNKNOWNEvaluation of a Prototype Diabetes Management System Applied to Insulin Initiation and TitrationNCT01698528 · 2012-10-01
COMPLETEDThe Efficacy and Safety of PAZ320 on PPG and Insulin Blood Levels in Type II Diabetic PatientsNCT04569214 · 2012-09-01
WITHDRAWNThe Effect of Mindfulness Based Stress Reduction in Patients With Painful Diabetic Peripheral NeuropathyNCT02127762 · 2012-09-01
COMPLETEDActivator and Type II DiabeticsNCT01782092 · 2012-08-01
COMPLETEDDiabetes Mellitus Community Based Screening in Minority PopulationsNCT01591525 · 2012-06-01
UNKNOWNPeriodontal Treatment Response in Type II Diabetic PatientsNCT01881074 · 2012-06-01
COMPLETEDEffects of Purple Vegetables on Cardiovascular Disease (CVD) Risk FactorsNCT01564498 · 2012-04-01
UNKNOWNClinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763NCT01619332 · 2012-03-01
COMPLETEDIntensive Discharge Intervention in DiabetesNCT02122926 · 2011-12-01
COMPLETEDBiospecimens for Identification of Diseases of the Pancreas.NCT01392027 · 2011-04-01
COMPLETEDThe Effect of Gastric Bypass Surgery on DiabetesNCT01330251 · 2011-01-01
COMPLETEDSafety and Efficacy Study of EndoBarrier in Subjects With Type II Diabetes and ObesityNCT00985114 · 2009-10-01
COMPLETEDFracture Risk With ThiazolidinedionesNCT01055223 · 2009-05-01
COMPLETEDCommon interventions
PlaceboDRUG6MetforminDRUG3AZD1656DRUG2EMPAGLIFLOZINDRUG2PioglitazoneDRUG2SitagliptinDRUG2[14C]HSK7653DRUG1AmilorideDRUG1Atorvastatin 40mg, QDDRUG1Best-Worst Scaling (Case 1)OTHER1Best-Worst Scaling (Case 2)OTHER1Blood DrawPROCEDURE1Brown seaweedDIETARY_SUPPLEMENT1Cardiac MRIPROCEDURE1Chiropractic AdjustmentOTHER1CKD-378 (low-dose)DRUG1CKD-378, QD, PO Drug: D745, D150, QD, PODRUG1CKD-387DRUG1CKD-393 formulation IDRUG1CKD-393 formulation IIDRUG1comparison dietOTHER1Compound plant extractsDIETARY_SUPPLEMENT1Control groupDIETARY_SUPPLEMENT1D484DRUG1D501, D759, H053DRUG1
Mapped drugs appearing in these trials
Shared trial participation only; not evidence of efficacy or approval.
Leading sponsors
Chong Kun Dang Pharmaceutical
4
AstraZeneca
3
Duke University
2
Johns Hopkins Bloomberg School of Public Health
2
Shandong Suncadia Medicine Co., Ltd.
2
Antenna Foundation
1
Aristotle University Of Thessaloniki
1
Baim Institute for Clinical Research
1
Boston Therapeutics
1
Brigham and Women's Hospital
1
Centre Hospitalier Sud Francilien
1
Centre Hospitalier Universitaire de Nīmes
1
Centre Hospitalier Universitaire Dijon
1
Daewoong Pharmaceutical Co. LTD.
1
Dow University of Health Sciences
1
Trial status mix
COMPLETED39
UNKNOWN16
RECRUITING5
TERMINATED3
NOT_YET_RECRUITING1
WITHDRAWN1
Phase mix
NA24
PHASE114
PHASE46
PHASE23
PHASE33
EARLY_PHASE12
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.